hifibio-logo
  • About
  • Pipeline
  • DIS® Platform
  • Partnering
  • News
  • Join Us

News

  • About
    • Company Overview
    • Leadership
    • Scientific Advisory Board
    • Board of Directors
    • Scientific Founders
    • Contact
  • Pipeline
    • Overview
    • Programs
      • EMUNKITUG (HFB200301)
      • HFB200603
      • NUVUSTOTUG (HFB301001)
      • HFB200604
      • HFB3024
  • DIS® Platform
  • Partnering
    • Partnerships
    • Open-Innovation Hub
  • News
  • Join Us

Latest News

Apr 29, 2025

HiFiBiO Therapeutics to Present Preclinical Data for A Novel Immunology Antibody at the 2025 Annual Meeting of the Clinical Immunology Society 

All  Filter By:

Jun 28, 2023

Robert Andtbacka, MD, CM joins HiFiBiO Therapeutics as Chief Medical Officer

hifibio-logo
Jun 23, 2023

HiFiBiO Therapeutics Announces First Patient First Visit for the Evaluation of HFB200301 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid Tumors

Logo-RGB-72
Biotech2050
|
Podcast
| Jun 14, 2023

HiFiBiO Therapeutics CEO Liang Schweizer Shares Her Professional Journey and the Company’s Pioneering DIS® Approach on the Biotech2050 Podcast

Apr 7, 2023

HiFiBiO Therapeutics Announces Oral Presentation at 2023 American Association for Cancer Research (AACR) Annual Meeting

Mar 6, 2023

Going Global: Insights on the Advantages of Biotech Globalization Published in Drug Discovery Today from HiFiBiO Therapeutics

< 1 2 3 4 5 6 … 17 >

oncoverity logo

© 2025 HiFiBiO Therapeutics, Inc.
All Rights Reserved.

Contact

contact@hifibio.com 237 Putnam Ave
Cambridge, MA 02139

Follow Us

Legal

Privacy Policy
Disclaimer
logo
  • About
    • Company Overview
    • Leadership
    • Scientific Advisory Board
    • Board of Directors
    • Scientific Founders
    • Contact
  • Pipeline
    • Overview
    • Programs
      • EMUNKITUG (HFB200301)
      • HFB200603
      • NUVUSTOTUG (HFB301001)
      • HFB200604
      • HFB3024
  • DIS® Platform
  • Partnering
    • Partnerships
    • Open-Innovation Hub
  • News
  • Join Us